Madina O. Bagova

Madina O. Bagova

Auto-generated profile, based on publicly available information

Madina O. Bagova

National Medical Research Center for Hematology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2021 in Oncohematology
Verified
Journal Article
Open access
PDF file
MBM. O. Bagova
M. O. Bagova
AMAminat Umaraskhabovna Magomedova
Aminat Umaraskhabovna Magomedova
SKS. K. Kravchenko
S. K. Kravchenko
YMYa. K. Mangasarova
Ya. K. Mangasarova
OMO. V. Margolin
O. V. Margolin
VSV. G. Savchenko
V. G. Savchenko
Background. Diffuse large B-cell lymphoma (DLBCL) is one of the most common and aggressive tumors of the lymphatic system. Despite the frequency of occurrence, there is no single algorithm for treating DLBCL patients with poor prognostic factors. R-CHOP therapy does not allow achieving long-term complete remissions. Therefore, there is a need for second and subsequent lines of therapy. At the same time, the effectiveness of each subsequent therapy is low, while the toxicity increases. There are many randomized trials of the DLBCL treatment; however, there are only a few studies on the comparative efficacy of high-dose chemotherapy at the induction stage.The objective of the study: the evaluation of the effectiveness and toxicity of R-DA-EPOCH and R-mNHL-BFM-90 induction courses in DLBCL patients with poor prognostic factors in a randomized multicenter clinical trial “DLBCL-2015”.Materials and methods. As of April 2021, 140 patients from 13 medical institutions in Russia were included in the randomized multicenter clinical trial DLBCL-2015. As part of this study, the analysis of pharmacoeconomic factors and effectiveness of combined immunochemotherapy R-DA-EPOCH and R-mNHL-BFM-90 in patients with prognostically unfavorable DLBCL had been performed. From January 2018 to April 2021, this study included 41 patients (21 men, 20 women) with a newly diagnosed DLBCL, with 2 or more factors of an unfavorable prognosis, who were treated at the National Research Center for Hematology of the Ministry of Health of the Russian Federation. Of these, 21 patients received R-DA-EPOCH, and 20, R-mNHL-BFM-90 therapy. Median age for R-DA-EPOCH patients was 52 years (range 30–64); for R-mNHL-BFM-90 patients, 40 years (range 18–60). All patients had high-intermediate and high risk according to the international (IPI) and age-adjusted (aaIPI) prognostic index. The primary protocol endpoints were rates of complete remission, partial remission, disease progression, and hematologic and non-hematologic toxicity. Side effects were assessed in accordance with the Common Terminology Criteria for Adverse Events (CTCAE) criteria.Results. By the end of 6 induction courses, the frequency of achieving complete remission on R-mNHL-BFM-90 therapy was 100 % (20/20) compared to R-DA-EPOCH, where the complete remission rate was 71.4 % (15/21) (p = 0.0097), partial remission and progression were 14.3 % (n = 3) and 14.3 % (n = 3), respectively. Hematological toxicity on therapy according to the R-mNHL-BFM-90 scheme exceeded that on R-DA-EPOCH in terms of myelotoxic agranulocytosis (p = 0.0536), anemia (p = 0.0464) and thrombocytopenia grade III–IV (p = 0.0206). When assessing non-hematological toxicity at the compared courses, no statistically significant differences were noted, all complications occurred with the same frequency.Conclusion. Treatment according to the R-mNHL-BFM-90 protocol is highly effective as first line therapy in high-intermediate and high-risk DLBCL patients. The hematologic toxicity is higher on the R-mNHL-BFM-90 than on the R-DA-EPOCH therapy, but it is acceptable. Non-hematological toxicity in both programs is comparable.

1 October 2024 in Clinical oncohematology
Verified
Journal Article
Open access
PDF file
YMYana Konstantinovna Mangasarova
Yana Konstantinovna Mangasarova
RAR. R. Abdurashidova
R. R. Abdurashidova
AMAminat Umaraskhabovna Magomedova
Aminat Umaraskhabovna Magomedova
OMO. V. Margolin
O. V. Margolin
ENE. S. Nesterova
E. S. Nesterova
EZE. E. Zvonkov
E. E. Zvonkov
BACKGROUND. Up to now, neither the optimal treatment regimen for primary mediastinal large B-cell lymphoma (PMBCL), nor poor/favorable prognostic factors for risk stratification at the disease onset have been found. The prognosis of PMBCL is determined by the depth of metabolic response by the time of treatment completion, which underlies a response-adapted strategy. Besides, PMBCL is an aggressive tumor occurring more commonly in young women of reproductive age, which requires the development of treatment strategy during pregnancy. AIM. To assess the efficacy of the response-adapted strategy in PMBCL treatment based on the DA-EPOCH-R program in remission induction with drug dose escalation and without subsequent radiotherapy, if a complete metabolic response is reported by PET-CT. MATERIALS & METHODS. This prospective single-center clinical trial enrolled 154 patients in the period from November 2012 to March 2023. The median age of the patients was 34 years (range 19–68 years). There were 51 (33.1 %) men and 103 (66.9 %) women, 11 of whom were at various gestational ages of pregnancy. RESULTS. The response-adapted treatment was completed in all 154 patients. Overall response was 93.5 % (144/154), complete remission was 78.6 % (121/154), and partial remission was 14.9 % (23/154). Progression was reported in 6.5 % (10/154) of patients. With a follow-up of 60 months, the overall, disease-free, progression-free, and event-free survival rates were 93 %, 98 %, 92 %, and 76 %, respectively. The median was not reached. Prior to chemotherapy, 11 pregnant women aged 21–37 (median 29 years) had been assessed. By the time of PMBCL diagnosis, the gestational age of them varied from 9 to 37 weeks (median 26 weeks). Immunochemotherapy was administered to 9 women during pregnancy. At the gestational age of 27–38 weeks (median 34 weeks) delivery was reported in 10 patients who gave birth to 11 children. The children showed no malformations. All women with PMBCL diagnosed during pregnancy and all their children had been followed-up by the time of this publication. CONCLUSION. The response-adapted strategy of PMBCL treatment with the DA-EPOCH-R regimen and drug dose escalation showed a high immediate and long-term efficacy as well as tolerable toxicity, which provided ground for the decision against radiotherapy, if a complete metabolic response was reported by PET-CT. The results of this trial establish the main goal of treating aggressive lymphomas during pregnancy which is saving of two lives. Delivery of newborns without malformations despite immunochemotherapy justifies the use of the DA-EPOCH-R program at the gestational age > 12 weeks.

11 November 2024 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
ENEkaterina Nesterova
Ekaterina Nesterova
JMJana K. Mangasarova
Jana K. Mangasarova
MBMadina O. Bagova
Madina O. Bagova
EFEkaterina A. Fastova
Ekaterina A. Fastova
AMAminat U. Magomedova
Aminat U. Magomedova
ТАТеляшов Максим Александрович
Теляшов Максим Александрович
Aim. To evaluate the effectiveness of autologous hematopoietic stem cell (HSC) mobilization with empegfilgrastim in patients with lymphoproliferative diseases (LPDs) and to identify prognostic factors affecting the effectiveness of mobilization. Materials and methods. The paper analyzes the effectiveness of HSC mobilization with Extimia® by JSC "BIOCAD" (INN: empegfilgrastim) in patients with LPDs. The study included 89 patients with LPDs (Hodgkin's lymphoma, B- and T-cell lymphomas, plasma cell tumors) who were treated in 5 research centers of the Russian Federation (in Moscow and St. Petersburg). The median age of patients was 39 (18–67) years. In 26 (29%) patients, HSC mobilization was performed "in a stable state of hematopoiesis" using only pegylated granulocyte colony-stimulating factor (PEG-G-CSF), and in 63 (71%) patients after chemotherapy (CT). Empegfilgrastim was administered as a single dose of 7.5 mg subcutaneously in two regimens: 24 hours after the end of CT or at a random time. Results. Two groups of patients were identified, analyzed, and compared: those with ineffective (n=23, 26%) and effective (n=66, 74%) HSC mobilization. Univariate and multivariate statistical analyses (binary logistic regression and multiple bidirectional binary logistic regression, respectively) were sequentially performed to determine the factors associated with ineffective mobilization. In a one-factor analysis, we studied the sex, age, diagnosis, bone/bone marrow involvement, the number of previous CT lines, the status of the disease (remission/no remission), the history of radiation therapy, the time interval from the administration of empegfilgrastim to the decision to perform leukapheresis, the mode of granulocytopoiesis stimulation ("in a stable state of hematopoiesis" or after CT), the leukocyte and platelet counts. The subsequent multifactorial analysis of the two selected parameters (diagnosis and time interval from drug administration to the decision to perform leukapheresis) showed the following statistically significant risk factors for ineffective mobilization: T-cell lymphoma; T-cell lymphoma versus other (combination) diagnoses (B-cell lymphoma, Hodgkin's lymphoma and plasma cell tumor): p=0.046, Wald test, odds ratio 4.18 (95% confidence interval 0.96–19.4). The time interval from the administration of empegfilgrastim to the first leukapheresis in the effective mobilization group depended on the diagnosis. The longest period was observed in patients with plasma cell tumors and the shortest in those with T-cell lymphomas: 10 (4–10) vs 5.5 (4–6) [p=0.01, Kruskal–Wallis test]. Empegfilgrastim proved equally effective for HSC mobilization both "on stable hematopoiesis" and after CT. Conclusion. The results of the first multicenter experience with Extimia® by JSC "BIOCAD" (INN: empegfilgrastim) to mobilize autologous HSCs in LPD patients demonstrate its high efficacy with a favorable safety and tolerability profile: 74% (66/89) successful mobilizations after a single administration of a fixed dose of the drug.

19 March 2024 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
LGL. G. Gorenkova
L. G. Gorenkova
YMYa. K. Mangasarova
Ya. K. Mangasarova
AKAlla Mikhailovna Kovrigina
Alla Mikhailovna Kovrigina
SKS. K. Kravchenko
S. K. Kravchenko
EKE. E. Klebanova
E. E. Klebanova
EZE. E. Zvonkov
E. E. Zvonkov
Introduction. Peripheral T-cell lymphomas (PTCL) — a rare group of lymphoproliferative diseases characterized by an aggressive course and an unfavorable prognosis. The group is represented by heterogeneous nosological forms, in which standard treatment options lead to unsatisfactory results. Aim: to present the protocols for the treatment of PTCLMain findings. In total, 12 years of experience in the treatment of 724 patients with T-cell lymphomas (430 patients with primary cutaneous forms, 110 patients with leukemic variants and 184 with peripheral T-cell lymphomas) has been accumulated. The treatment results and therapeutic algorithms were analyzed. In the general group of patients, the 3-year overall survival (OS) and relapse-free survival (EFS) were 76 % and 70 %, respectively. The best treatment results were achieved in the groups of intestinal T-cell lymphoma, specifically (EATL), and angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell ALK-positive lymphoma (ALCL ALK+), and the worst — in the group of ALCL ALK- (5-year EFS 31 %). High-dose chemotherapy under the NHL BFM-90 program in the treatment of ALK+ ALCL allows achieving 10-year OS and EFS 87 % and 84 %, respectively, but the less toxic CHOEP program was not inferior in effectiveness: 5-year OS and EFS amounted to 93 % and 88 %, respectively. High survival rates of patients with EATL were achieved with the use of high-dose chemotherapy according to the LB-M-04 program followed by auto-HSCT in the first line of therapy: 5-year OS and EFS amounted to 79 % and 74 %, respectively. The positive role of AITL maintenance therapy has been shown: 5-year OS and EFS during its implementation amounted to 75 % and 49 % versus 41 % and 20 % in the absence of it. In the protocols for the treatment of extranodal NK/T cell lymphoma, radiation therapy was used in the first line of therapy, 5-year OS and EFS were 60 % and 42 %, respectively. The role of autologous hematopoietic stem cell transplantation (auto-HSCT) in all PTCL was evaluated: 5-year OS and EFS were 82 % and 58 % compared with 67 % and 49 % without auto-HSCT. The transplantation of allogeneic hematopoietic stem cells (allo-HSCT), even in the treatment of relapses of the disease, has shown its effectiveness: 9 out of 11 patients are alive and remain in remission of the disease.

20 November 2023 in Pharmateca
Verified
Journal Article
Closed access
MBM.O. Bagova Bagova
M.O. Bagova Bagova
YMY.K. Mangasarova Mangasarova
Y.K. Mangasarova Mangasarova
AMA.U. Magomedova Magomedova
A.U. Magomedova Magomedova
OMO.V. Margolin Margolin
O.V. Margolin Margolin
ENE.S. Nesterova Nesterova
E.S. Nesterova Nesterova
EZE.E. Zvonkov Zvonkov
E.E. Zvonkov Zvonkov

23 March 2026 in Oncohematology
Verified
Journal Article
Open access
ENEkaterina Nesterova
Ekaterina Nesterova
YMY. K. Mangasarova
Y. K. Mangasarova
III. L. Israilova
I. L. Israilova
AMAminat Umaraskhabovna Magomedova
Aminat Umaraskhabovna Magomedova
MBM. O. Bagova
M. O. Bagova
EPE. N. Parovichnikova
E. N. Parovichnikova
Background. In Russian clinical practice, there is no systematic information on patients with follicular lymphoma (FL) relapses after first-line therapy, and only isolated data are presented regarding the frequency of early and late relapses in the domestic population, first-line therapy regimens used in these patients, the dynamics of treatment response, timing of relapse, and second-line therapy regimens. A detailed analysis of a large cohort of patients with relapsed FL, including detailed clinical, laboratory, morphoimmunohistochemical, and molecular genetic characteristics, the treatments administered at onset and during relapse, as well as the identification of factors correlating with the risk of early progression, is of great scientific and practical interest. This is the focus of this study. Our results will be aimed at optimizing treatment and improving the prognosis of FL patients in Russia who have received second-line therapy. Aim. To describe changes in the therapeutic landscape of first-line FL therapy from 2001 to 2025 for patients receiving treatment at the National Medical Research Center for Hematology; to analyze the effectiveness of the therapeutic protocols used; to study cases of treatment resistance and identify significant factors influencing the prognosis of the disease; as well as to determine outcomes for patients with the first early relapse of nodal FL. Materials and methods. A retrospective and prospective study conducted from 2001 to 2025 at the National Medical Research Center of Hematology (Moscow) included 445 patients with newly diagnosed FL of cytological types 1–2 and 3A (World Health Organization, 2017). The median follow-up was 95 (1–251) months. All patients were treated according to the criteria of the Groupe d’Etude des Lymphomes Folliculaires. All patients included in the study were divided into two groups: those who received initial treatment between 2001 and 2022 (the historical control group; n = 374) and those who received initial treatment between 2022 and 2025 according to the new FL-2022 risk-based differentiated treatment protocol for patients with nodal FL (n = 71). Data for the two groups were analyzed separately. Results. With a median follow-up of 98 (1–251) months, the 2-year, 5-year, and 10-year overall survival of 374 patients from the historical control group (2001–2022) were 93, 90, and 85 %, respectively; 2-year, 5-year, and 10-year event-free survival were 82, 71, and 55 %, respectively. With high-dose chemotherapy, compared with standard regimens, the proportion of progressions / relapses was significantly lower (26 % versus 40 %; p = 0.01), but if events occurred, they were predominantly early (72 % versus 58 %; p = 0.2). According to the results of multivariate analysis, independent prognostic risk factors for disease progression within 24 months after the start of therapy (POD24) were identified: absence of BCL2 gene rearrangement (odds ratio 3.52 (1.89–6.55); p 0.0001) and 3A cytological type (odds ratio 3.8 (1.61–0.16); p = 0.0033). During second-line therapy in the first early relapse / progression after R-B (rituximab + bendamustine), R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone) and autologous hematopoietic stem cell transplantation, complete remission was achieved in only 38 % of patients, and after R-DHAP it was not achieved in any case. With therapy according to the FL-2022 protocol (2022–2025), with a median follow-up of 23 months, 2-year overall survival was 100 %, 2-year event-free survival was 97 %. Second-line therapy was required in only 6 % of patients. Conclusion. The development of early relapse / progression has a critical impact on the survival prognosis of FL patients. The use of a differentiated treatment protocol for patients with nodal FL (FL-2022), based on clinical, morphological, immunohistochemical, and genetic prognostic factors, has significantly improved treatment outcomes and reduced the risk of POD24. When FL first relapses, there is no uniform treatment standard, and the regimens used vary greatly. Treatment outcomes in the first relapse remain modest, especially for the high-risk POD24 group, necessitating a change in the treatment paradigm for this patient group.